HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...

Get Instant Summarized Text (Gist) A membrane protein, FXYD2, has been identified as a marker that distinguishes functional, mature stem cell–derived islet organoids from non-functional ones.

From mixed to matched: new marker pinpoints therapeutically relevant stem cell–derived islets Human pluripotent stem cell–derived islets hold great promise as a functional cure for diabetes.

Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently ...

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

Our study addresses this challenge by resolving the heterogeneity of human stem cell–derived islet organoids and introducing a functional marker to isolate transplant-ready islets," said Dr ...

However, the lack of reliable markers to identify truly functional, stem cell–derived islets has hindered the consistent production needed for clinical application.